Share on LinkedInShare on LinkedIn

ARTICLE · 23 JANUARY 2014

Federal Court Finds Biologics Patent Valid And Infringed

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

On January 17, 2014, the Federal Court issued its first biologics patent decision since the 1999 decision of Kirin-Amgen Inc. v. Hoffmann-La Roche Ltd.

CanadaIntellectual Property

On January 17, 2014, the Federal Court issued its first biologics patent decision since the 1999 decision of Kirin-Amgen Inc. v. Hoffmann-La Roche Ltd.1 After an 11 day trial, the Court held that Abbvie's patent was valid and infringed by Janssen's drug ustekinumab (STELARA®), which is a human monoclonal antibody marketed in Canada for the treatment of psoriasis (Abbvie Corporation v. Janssen Inc., 2014 FC 55, per Hughes J).

Abbvie's patent

Abbvie's patent relates to human antibodies and their use to treat various diseases.  Antibodies used as medicinal products are part of a class of drugs often referred to as "biologics". Biologics are drugs that are created by biological processes, as opposed to small molecule drugs which are synthesized by chemical means.  

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from